OFIX Stock Analysis: Orthofix Medical | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 466m USD | 12M Return: 2.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.90M
Qual. Beats: 2
Rev. Trend: 84.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Orthofix Medical Inc. (NASDAQ: OFIX) is a small-cap medical technology company headquartered in Lewisville, Texas, that develops and markets devices and biologics for spinal and orthopedic conditions. The company operates in roughly seven countries and reports through two business segments: Global Spine and Global Limb Reconstruction.
The Global Spine segment manufactures bone growth stimulation devices used to enhance spinal fusion, sells a portfolio of spine fixation implant products, and offers bone graft substitutes such as demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers. The segment also markets navigation technology for spinal and cranial procedures, including the 7D FLASH Navigation System, which uses machine-vision and optical innovations to assist surgeons in placing implants.
The Global Limb Reconstruction segment focuses on the historically underserved limb reconstruction market, addressing deformity correction, limb lengthening, complex fracture management, and limb preservation. Its offerings include external and internal fixation products paired with enabling digital technologies intended to support the full continuum of patient care, from pre-operative planning through recovery.
Orthofix sells primarily through a network of distributors and direct sales representatives to hospitals, ambulatory surgery centers, outpatient facilities, and other healthcare providers. The company was founded in 1980, was previously known as Orthofix International N.V., and adopted its current name in July 2018. As a participant in the Health Care Equipment sub-industry, OFIX competes in the broader medical device market, where spine surgery and orthopedic fixation represent large and growing addressable markets driven by aging populations and rising rates of outpatient procedures performed in ambulatory surgery centers.
- SeaSpine merger integration lifts Global Spine segment revenue
- 7D FLASH Navigation adoption accelerates spine procedure volume
- Global Limb Reconstruction expands in underserved deformity correction market
| Net Income: -60.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 36.41% < 20% (prev 30.60%; Δ 5.81% < -1%) |
| CFO/TA 0.04 > 3% & CFO 34.9m > Net Income -60.0m |
| Net Debt (155.0m) to EBITDA (94.5m): 1.64 < 3 |
| Current Ratio: 2.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.5m) vs 12m ago 3.19% < -2% |
| Gross Margin: 69.02% > 18% (prev 67.15%; Δ 1.86% > 0.5%) |
| Asset Turnover: 96.55% > 50% (prev 97.74%; Δ -1.19% > 0%) |
| Interest Coverage Ratio: -2.19 > 6 (EBIT TTM -40.9m / Interest Expense TTM 18.6m) |
| A: 0.34 (Total Current Assets 461.5m - Total Current Liabilities 161.0m) / Total Assets 886.6m |
| B: -0.44 (Retained Earnings -389.2m / Total Assets 886.6m) |
| C: -0.05 (EBIT TTM -40.9m / Avg Total Assets 854.9m) |
| D: 0.96 (Book Value of Equity 435.2m / Total Liabilities 451.4m) |
| Altman-Z'' = 1.48 = BB |
| DSRI: 1.02 (Receivables 137.8m/131.9m, Revenue 825.4m/804.5m) |
| GMI: 0.97 (GM 67.15% / 69.02%) |
| AQI: 0.97 (AQ_t 0.34 / AQ_t-1 0.35) |
| SGI: 1.03 (Revenue 825.4m / 804.5m) |
| TATA: -0.11 (NI -60.0m - CFO 34.9m) / TA 886.6m) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 11.63 with a total of 216,313 shares traded. Over the past week, the price has changed by +17.00%, over one month by +19.53%, over three months by -6.06% and over the past year by +2.38%.
Current recommended Stop Loss: 10.90 (which is 6.3% or 1.3 ATR below the current price).
Orthofix Medical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OFIX.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.5 | 33.3% |
P/E Forward = 500.0
P/S = 0.5652
P/B = 1.0747
P/EG = 48.825
Revenue TTM = 825.4m USD
EBIT TTM = -40.9m USD
EBITDA TTM = 94.5m USD
Long Term Debt = 221.3m USD (from longTermDebt, last quarter)
Short Term Debt = 115k USD (from shortTermDebt, last quarter)
Debt = 275.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.9m
Net Debt = 155.0m USD (calculated: Debt 275.3m - CCE 120.3m)
Enterprise Value = 621.5m USD (466.5m + Debt 275.3m - CCE 120.3m)
Interest Coverage Ratio = -2.19 (Ebit TTM -40.9m / Interest Expense TTM 18.6m)
EV/FCF = -171.3x (Enterprise Value 621.5m / FCF TTM -3.63m)
FCF Yield = -0.58% (FCF TTM -3.63m / Enterprise Value 621.5m)
FCF Margin = -0.44% (FCF TTM -3.63m / Revenue TTM 825.4m)
Net Margin = -7.27% (Net Income TTM -60.0m / Revenue TTM 825.4m)
Gross Margin = 69.02% ((Revenue TTM 825.4m - Cost of Revenue TTM 255.7m) / Revenue TTM)
Gross Margin QoQ = 70.94% (prev 64.59%)
Tobins Q-Ratio = 0.70 (Enterprise Value 621.5m / Total Assets 886.6m)
Interest Expense / Debt = 6.77% (Interest Expense 18.6m / Debt 275.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -32.3m (EBIT -40.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.87 (Total Current Assets 461.5m / Total Current Liabilities 161.0m)
Debt / Equity = 0.63 (Debt 275.3m / totalStockholderEquity, last quarter 435.2m)
Debt / EBITDA = 1.64 (Net Debt 155.0m / EBITDA 94.5m)
Debt / FCF = -42.72 (negative FCF - burning cash) (Net Debt 155.0m / FCF TTM -3.63m)
Total Stockholder Equity = 446.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.02% (Net Income -60.0m / Total Assets 886.6m)
RoE = -13.44% (Net Income TTM -60.0m / Total Stockholder Equity 446.5m)
RoCE = -6.12% (EBIT -40.9m / Capital Employed (Equity 446.5m + L.T.Debt 221.3m))
RoIC = -4.72% (negative operating profit) (NOPAT -32.3m / Invested Capital 684.4m)
WACC = 6.97% (E(466.5m)/V(741.8m) * Re(7.92%) + D(275.3m)/V(741.8m) * Rd(6.77%) * (1-Tc(0.21)))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 3.75%
[DCF] Fair Price = unknown (Cash Flow -3.63m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.89 | # QB: 2
Revenue Correlation: 84.68 | Revenue CAGR: 9.51% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.08 | Chg30d=+60.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.30 | Chg30d=+57.89% | Revisions=+25% | GrowthEPS=-38.5% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=0.84 | Chg30d=+18.31% | Revisions=-25% | GrowthEPS=+180.0% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: -29% (up=1, down=3)